---
title: "KESTRA MEDICAL TECHNOLOGIES, LTD. FY 2026: Revenue $95.1M, Net income $(131.6M) — 10-K Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292678150.md"
description: "Kestra Medical Technologies reported FY2026 revenue of $95.1M, a 59% increase from FY2025, driven by higher patient volume for its ASSURE WCD device. However, the company posted a net loss of $(131.6M), widening from $(126.1M) in the prior year. Revenue growth was supported by expanded commercial operations across 130 U.S. territories and improved operational efficiency, which reduced cost per patient by 18%. The majority of revenue stems from Medicare, Medicaid, and private payors."
datetime: "2026-07-14T21:25:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292678150.md)
  - [en](https://longbridge.com/en/news/292678150.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292678150.md)
---

# KESTRA MEDICAL TECHNOLOGIES, LTD. FY 2026: Revenue $95.1M, Net income $(131.6M) — 10-K Summary

Kestra Medical Technologies, Ltd. reported fiscal 2026 revenue of $95.1M, up 59% from $59.8M a year earlier, while reporting a net loss attributable to common shareholders of $(131.6M) versus $(126.1M) in FY 2025.

**Financial Highlights**

-   Revenue was $95.1M for FY 2026, compared with $59.8M in FY 2025; YoY change 59%.
-   Net income (net loss attributable to common shareholders) was $(131.6M) for FY 2026, compared with $(126.1M) in FY 2025 (loss widened).
-   Diluted earnings per share: not reported in the provided sections and therefore omitted.

**Business Highlights**

-   Revenue growth was driven by a 58% increase in patient volume using the ASSURE WCD following commercial launch post-PMA.
-   Majority of revenue came from direct billing to Medicare, Medicaid and private payors; the company holds Medicare supplier status to support commercial scaling.
-   Commercial footprint expanded to roughly 130 U.S. territories from 80, supported by substantial hiring and higher sales and marketing investment.
-   Operational efficiency improved: cost per patient declined about 18% through greater rental-pool utilization, lower disposable costs and manufacturing gains.
-   Product and platform momentum includes ongoing clinical programs, digital engagement tools and an expanded rental fleet to support continued growth.

Original SEC Filing: KESTRA MEDICAL TECHNOLOGIES, LTD. \[ KMTS \] - 10-K - Jul. 14, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [KMTS.US](https://longbridge.com/en/quote/KMTS.US.md)

## Related News & Research

- [Kestra Medical CFO Mahboob Vaseem disposes of common shares worth $680.645,77](https://longbridge.com/en/news/295585382.md)
- [Kestra Medical CFO Vaseem Mahboob sells common shares worth $172,500.19](https://longbridge.com/en/news/295154029.md)
- [Kestra Medical Technologies Insiders Sold Shares Worth Over $1.8M](https://longbridge.com/en/news/294747798.md)
- [High Roller Technologies to present at Sidoti Virtual Micro-Cap Conference](https://longbridge.com/en/news/295404657.md)
- [UFP Technologies Executive Chairman R. Jeffrey Bailly lepas 13.011 saham senilai USD 4,12 juta](https://longbridge.com/en/news/295571524.md)